Novartis is expanding its radioligand therapy manufacturing in the US and entered a global licensing deal with SciNeuro for a novel Alzheimer's antibody. It also secured a worldwide license for a peptide-based radioligand therapy asset from Zonsen PepLib. The company's pipeline is strengthened by promising assets like iptacopan for myasthenia gravis and ianalumab for lupus, alongside the pending acquisition of Avidity Biosciences. Management reiterated a focus on value-creating, oncology-focused business development deals.